These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 17458165)

  • 41. [Small interfering RNA mediated multi-target therapy of cancer].
    Shao RG
    Yao Xue Xue Bao; 2009 Mar; 44(3):219-25. PubMed ID: 19449517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Specific inhibition of orthopoxvirus replication by a small interfering RNA targeting the D5R gene.
    Vigne S; Germi R; Duraffour S; Larrat S; Andrei G; Snoeck R; Garin D; Crance JM
    Antivir Ther; 2008; 13(3):357-68. PubMed ID: 18572748
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Therapeutic oligonucleotides: the state-of-the-art in purification technologies.
    Sanghvi YS; Schulte M
    Curr Opin Drug Discov Devel; 2004 Nov; 7(6):765-76. PubMed ID: 15595437
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Chemotherapy for recurrent and metastatic cervical cancer.
    Tao X; Hu W; Ramirez PT; Kavanagh JJ
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S67-71. PubMed ID: 18533239
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Overview of target validation and the impact of oligonucleotides.
    Jones SW; Lindsay MA
    Curr Opin Mol Ther; 2004 Oct; 6(5):546-50. PubMed ID: 15537056
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human papillomavirus testing for primary cervical cancer screening.
    Grce M; Davies P
    Expert Rev Mol Diagn; 2008 Sep; 8(5):599-605. PubMed ID: 18785808
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Future prospects of RNA interference in cancer therapies].
    Ashihara E
    Rinsho Ketsueki; 2009 Oct; 50(10):1577-88. PubMed ID: 19915369
    [No Abstract]   [Full Text] [Related]  

  • 48. Oligonucleotide delivery: a patent review (2010 - 2013).
    Grijalvo S; Aviñó A; Eritja R
    Expert Opin Ther Pat; 2014 Jul; 24(7):801-19. PubMed ID: 24798406
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antisense treatments for biothreat agents.
    Warfield KL; Panchal RG; Aman MJ; Bavari S
    Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer.
    Mullenders J; Bernards R
    Oncogene; 2009 Dec; 28(50):4409-20. PubMed ID: 19767776
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tissue-Specific Delivery of Oligonucleotides.
    Xia X; Pollock N; Zhou J; Rossi J
    Methods Mol Biol; 2019; 2036():17-50. PubMed ID: 31410789
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.
    Ngamcherdtrakul W; Castro DJ; Gu S; Morry J; Reda M; Gray JW; Yantasee W
    Cancer Treat Rev; 2016 Apr; 45():19-29. PubMed ID: 26930249
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human Papillomavirus: Current and Future RNAi Therapeutic Strategies for Cervical Cancer.
    Jung HS; Rajasekaran N; Ju W; Shin YK
    J Clin Med; 2015 May; 4(5):1126-55. PubMed ID: 26239469
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Anti-genes: siRNA, ribozymes and antisense.
    Scanlon KJ
    Curr Pharm Biotechnol; 2004 Oct; 5(5):415-20. PubMed ID: 15544489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RNA-based therapeutics: current progress and future prospects.
    Burnett JC; Rossi JJ
    Chem Biol; 2012 Jan; 19(1):60-71. PubMed ID: 22284355
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oligonucleotide-based therapy for neurodegenerative diseases.
    Magen I; Hornstein E
    Brain Res; 2014 Oct; 1584():116-28. PubMed ID: 24727531
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Intranasal antisense therapy: preclinical models with a clinical future?
    Bitko V; Barik S
    Curr Opin Mol Ther; 2007 Apr; 9(2):119-25. PubMed ID: 17458164
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Oral delivery of small RNA and DNA.
    Forbes DC; Peppas NA
    J Control Release; 2012 Sep; 162(2):438-45. PubMed ID: 22771979
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Pharmacology of RNA Interference-Based Therapeutics: A Summary Based on Food and Drug Administration-Approved Small Interfering RNAs.
    Jing X; Arya V; Reynolds KS; Rogers H
    Drug Metab Dispos; 2023 Feb; 51(2):193-198. PubMed ID: 36332914
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A status update of modified oligonucleotides for chemotherapeutics applications.
    Sanghvi YS
    Curr Protoc Nucleic Acid Chem; 2011 Sep; Chapter 4():Unit 4.1.1-22. PubMed ID: 21901670
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.